Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 109Endometrial Neoplasms 16Neoplasm Metastasis 10Polycystic Ovary Syndrome 9Ovarian Neoplasms 7Neoplasms 7Advanced Breast Cancer 5Triple Negative Breast Neoplasms 4Prostatic Neoplasms 4Fallopian Tube Neoplasms 4Recurrence 3Infertility 3Carcinoma, Intraductal, Noninfiltrating 3Breast Neoplasms, Male 3Squamous Cell Carcinoma of Head and Neck 2Progesterone Resistance 2Neoplasms by Site 2Hereditary Sensory and Autonomic Neuropathies 2Head and Neck Neoplasms 2HR+/HER2- Breast Cancer 2Estrogen Receptor-positive Breast Cancer 2Endometrial Hyperplasia 2Cystadenocarcinoma, Serous 2Carcinoma, Non-Small-Cell Lung 2Breast Diseases 2Breast Cancer Metastatic 2Breast Cancer Female 2Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Small Cell Lung Carcinoma 1

Interventions

Letrozole 2trametinib 1ribociclib 1niraparib 1liposomal doxorubicin 1Topotecan 1Taxes 1Tamoxifen 1Specimen Handling 1Paclitaxel 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Doxorubicin 1CTLA-4 Antigen 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Cystadenocarcinoma, Serous × Letrozole × 1 year × Clear all
NCT03673124 2025-12-23

Ribociclib and Letrozole Treatment in Ovarian Cancer

GOG Foundation

Phase 2 Active not recruiting
51 enrolled 19 charts

Cystadenocarcinoma, Serous

NCT02101788 2025-11-13

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

National Cancer Institute (NCI)

Phase 2/3 Completed
260 enrolled 20 charts

Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡